It’s that time of year again! Many of ARLG’s top leaders and experts will be at IDWeek 2022 discussing the latest AMR topics. Whether you are attending virtually or in person, plan ahead to join your favorite sessions.
Be sure you catch this year’s Maxwell Finland Lecture delivered by ARLG primary investigator, Helen Boucher, MD, FACP, FIDSA, on October 20. Use the guide below to find more exciting sessions and posters you won’t want to miss.
Learn more and view OnDemand content at IDWeek.org
IDWeek 2022 ARLG Sessions
| Day | Time (EDT) | Session Title | Presentation title | Moderators | Speakers |
|---|---|---|---|---|---|
| Oct. 18 | 11:30 am - 12:30 pm | PW02 - Best Practices for Antibiotic Stewardship Programs | Pseudomonas aeruginosa and Enterobacter cloacae: Our Unsung Nemeses | Pranita Tamma | |
| Oct. 18 | 2:25 - 3:40 pm | PW02 - Best Practices for Antibiotic Stewardship Programs | Pro-Con Debate: FQ Prophy in HCT | Ghady Haidar | |
| Oct. 18 | 3:00 - 4:00 pm | PW03 - Research Training Programs, Careers and Grant Writing Strategies for ID Physician-Scientists | Additional Funding Opportunities Outside of NIH Presentations with Q&A | Sara Cosgrove | |
| Oct. 19 | 10:45 am - 12:00 pm | PW04 - Fellows' Day Workshop | Careers in Research | Cesar Arias | |
| Oct. 20 | 8:00 – 9:00 am | 10- Effective Collaborations Between Stewards and the Microbiology Laboratory | Pranita Tamma | ||
| Oct. 20 | 8:00 – 8:30 am | 10- Effective Collaborations Between Stewards and the Microbiology Laboratory | How Stewards Can Transform the Science of Antibiotic Breakpoints Into Clinical Practice Recommendations | Amy Mathers | |
| Oct. 20 | 8:00 – 9:00 am | 18 - New Antimicrobials and ID Diagnostics in the Pipeline - Bacterial | Cesar Arias, David van Duin | ||
| Oct. 20 | 9:15 – 10:00 am | 19 - Maxwell Finland Lecture | Running to Stand Still: Progress and Perils with AMR | Helen Boucher | |
| Oct. 20 | 10:30 – 11:45 am | 21 - Diagnostic Clinical Cases | Jennifer Dien Bard (panelist) | ||
| Oct. 20 | 10:30 – 11:45 am | 22 - Clinical Trials That May Change Your Practice | Thomas Holland | ||
| Oct. 20 | 11:20 – 11:45 am | 29 - What's New in Fungal Therapeutics and Diagnostics in Transplant? | Antifungal Susceptibility Testing Challenges | Mariana Castanheira | |
| Oct. 20 | 10:30-11:45 am | 32 - MDROs Across the Spectrum | Anthony Harris | ||
| Oct. 20 | 1:45-3:00 pm | 71 - Circadian Clock, Hormones and Host Defenses Against Infections | Anne-Catrin Uhlemann | ||
| Oct. 20 | 1:45-3:00 pm | 78 – Antimicrobial Clinical Trials (Bacterial and Viral) | Pranita Tamma | ||
| Oct. 20 | 3:15-4:30 pm | 89 - New Battles With Old Foes: Addressing Syphilis and Drug-Resistant Neisseria gonorrhea | Anne-Catrin Uhlemann | ||
| Oct. 20 | 3:15-4:30 pm | 95 - Diagnostic Stewardship for Common Syndromes | Sonali Advani | ||
| Oct. 21 | 8:00 – 8:30 am | 104 - Overdiagnosis of Infections: Cracking the Code! | The Urine Story | Sonali Advani | |
| Oct. 21 | 8:00 – 8:30 am | 105 - Slow and Steady: Insights Into Nontuberculous Mycobacteria and Treatment | Anne-Catrin Uhlemann | ||
| Oct. 21 | 8:00 –8:30 am | 106 - Still the One? Debating Vancomycin as First Line MRSA Agent in New Era of AUC/MIC Dosing and Monitoring | Pro-Vancomycin Is Still the One | Marc Scheetz | |
| Oct. 21 | 8:00 –9:00 am | 110 - New Antimicrobials and ID Diagnostics in the Pipeline - Diagnostics | Angela Caliendo | ||
| Oct. 21 | 10:30-11:45 am | 114 - Clinical Controversies in the Treatment of S. aureus Bacteremia | Thomas Holland | ||
| Oct. 21 | 10:30-11:45 am | 115 - Ditching the Dogma: Antimicrobial Stewardship Myth Busters | Pranita Tamma | ||
| Oct. 21 | 10:55-11:20 am | 115 - Ditching the Dogma: Antimicrobial Stewardship Myth Busters | Myth: Trimethoprim-Sulfamethoxazole Is Not Effective for the Treatment of Skin and Soft Tissue Infections Involving Beta-Hemolytic Streptococci | Sarah Doernberg | |
| Oct. 21 | 12:15-12:45 pm | 157 - Rapid Fire Poster Session: Updates in Diagnostics | Patricia Simner | ||
| Oct. 21 | 1:45-3:00 pm | 163 - Double Trouble: How Viruses and Bacterial Interactions Affect the Pathogenesis of Pneumonia | Anne-Catrin Uhlemann | ||
| Oct. 21 | 2:35-3:00 pm | 166 - Hot Topics in Pediatric Infectious Diseases | The Role of the Microbiome in Childhood Infections | Matthew Kelly | |
| Oct. 21 | 1:45-3:00 pm | 167 - Improving the Identification of Sepsis | The Stewardship of Sepsis: A Report From the IDSA Sepsis Task Force | Sara Cosgrove | Sara Cosgrove |
| Oct. 21 | 1:45-2:10 pm | 170 - What the Big Beasts of Hospital Epidemiology and Antimicrobial Stewardship Did During COVID-19 | MDROs in the COVID Era | Robert Bonomo | |
| Oct. 21 | 1:45-3:00 pm | 171 - Endocarditis & BSI | David van Duin | ||
| Oct. 21 | 1:45-3:00 pm | 175 - Updates in Diagnostics | Ahmed Babiker | ||
| Oct. 21 | 3:15-4:30 pm | 179 - Bad Bug, Bad Bugs: Whatcha Gonna Do (2.0)? | Ample Choices? Prescribing Considerations for AmpC β-lactamase-producing Enterobacterales (AmpC-E) | Judith Anesi | |
| Oct. 21 | 3:15-4:30 pm | 180 - Behind the Curtain: New Insights Into the Pathogenesis of Candida Infections | Anne-Catrin Uhlemann | ||
| Oct. 21 | 3:15-4:30 pm | 181 - Follow-Up Blood Cultures in Bloodstream Infection: Who Needs 'Em? | Thomas Holland | ||
| Oct. 21 | 3:15-4:30 pm | 185 - Promise and Perils of New Beta-Lactam Agents | Yohei Doi | ||
| Oct. 21 | 4:05-4:30 pm | 185 - Promise and Perils of New Beta-Lactam Agents | Considerations in the Micro Lab | Jennifer Dien Bard | |
| Oct. 22 | 8:00-9:00 am | 193 - Finding the Needle in the Haystack: New Biomarkers of Infections | Anne-Catrin Uhlemann | ||
| Oct. 22 | 8:00-9:00 am | 195 - Oral Treatment of Osteoarticular Infections, Bacteremia and Endocarditis | Busting 75 Years of ID Myths: Oral Antibiotic Therapy for Osteomyelitis, Bacteremia and Endocarditis | Brad Spellberg | Brad Spellberg |
| Oct. 22 | 10:30-11:45 am | 209 - Putting the Value of ID Into Practice | Case Vignette | Cesar Arias | |
| Wrap Up and Q&A | |||||
| Oct. 22 | 1:45-3:00 pm | 249 - Disarming Bacterial Destruction: Toxins as Therapeutic Targets | Anne-Catrin Uhlemann | ||
| Oct. 22 | 1:45-3:00 pm | 254 - Optimizing Stewardship Interventions in Challenging Populations | Pranita Tamma | ||
| Oct. 22 | 2:35-3:00 pm | 255 - Perfectionism and the Fear of Failure | Leadership, Perfectionism and Expectations | Latania Logan | |
| Oct. 22 | 3:15-4:30 pm | 263 - Knocking Out the Nonfermenters: Focus on Treatment Through Case Review | Yohei Doi | Michael Satlin (Panelist) | |
| Oct. 22 | 3:40-4:05 pm | 267 - 2022 IDSA Guideline Update | Intra-Abdominal Infections | Robert Bonomo | |
| Oct. 22 | 4:05-4:30 pm | 267 - 2022 IDSA Guideline Update | IDSA Guidance on the Treatment of Antimicrobial-Resistant Infections | Pranita Tamma |
IDWeek 2022 ARLG Posters
| Day, Time | Number | Title | Authors |
|---|---|---|---|
| Oct. 22 12:15-1:30 pm | 229 | Molecular and Clinical Epidemiology of Carbapenem-resistant E. coli isolates from different global regions (CRACKLE-2) | Boutzoukas AE, Komarow L, Chen L, Baum K, Fowler V, Arias C, Hill C, Hanson B, Kreiswirth B, Wang M, Paterson D, Bonomo R, van Duin D |
| Oct. 22 12:15-1:30 pm | 232 | Population Pharmacokinetics (PopPK) of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE) | Lodise TP, O'Donnell JN, Balevic S, Liu X, Gu K, George J, Raja S, Zaharoff S, Schwager N, Fowler VG Jr., Chambers HF; Antibiotic Resistance Leadership Group |
| Oct. 22 12:15-1:30 pm | 233 | Safety of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE) | Lodise TP, O'Donnell N, Raja S, Balevic S, Guptill J, Schwager N, Zaharoff S, Fowler VG Jr., Ghazaryan V, Beresnev T, Wall A, Wiegand K, Chambers HF, Antibiotic Resistance Leadership Group |